257 related articles for article (PubMed ID: 15864584)
1. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
3. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
5. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
6. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
[TBL] [Abstract][Full Text] [Related]
7. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.
Sato N; Saga T; Sakahara H; Nakamoto Y; Zhao S; Kuroki M; Iida Y; Endo K; Konishi J
Jpn J Cancer Res; 2000 Jun; 91(6):622-8. PubMed ID: 10874215
[TBL] [Abstract][Full Text] [Related]
8. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
[TBL] [Abstract][Full Text] [Related]
9. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
[TBL] [Abstract][Full Text] [Related]
10. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
12. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.
Li GP; Wang YX; Huang K; Zhang H; Zhang CF
World J Gastroenterol; 2005 Apr; 11(13):1917-21. PubMed ID: 15800980
[TBL] [Abstract][Full Text] [Related]
13. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
14. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
16. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
Devys A; Thedrez P; Gautherot E; Faivre-Chauvet A; Saï-Maurel C; Rouvier E; Auget JL; Barbet J; Chatal JF
Int J Cancer; 1996 Sep; 67(6):883-91. PubMed ID: 8824563
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
19. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
Gautherot E; Bouhou J; Le Doussal JM; Manetti C; Martin M; Rouvier E; Barbet J
Cancer; 1997 Dec; 80(12 Suppl):2618-23. PubMed ID: 9406716
[TBL] [Abstract][Full Text] [Related]
20. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody.
Rauscher A; Frindel M; Maurel C; Maillasson M; Le Saëc P; Rajerison H; Gestin JF; Barbet J; Faivre-Chauvet A; Mougin-Degraef M
Nucl Med Biol; 2014 May; 41 Suppl():e66-74. PubMed ID: 24485990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]